Total Funding
63
68
Total FundingVenture - Series Unknown raised
Growth Score 63 in past quarter
-6 pts
Heat Score 68 in past quarter
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
95319
ADVITOS developed the CE-marked and globally patented ADVOS technology.
Philipp J. Stolka: Head of Intelligent Systems and Data ManagementPast Role: Clear Guide Medical, CTO and Co-Founder- Bernhard Kreymann: Founder & CEO
About the Company
ADVOS is the world’s first method for the combined multi-organ support of liver, lung, kidney, and acid-base balance. Based on the principle of albumin dialysis, ADVOS allows extracorporeal fluid-based elimination of CO2, hepatic toxins, water-soluble and protein-bound nephrotoxins, as well as the correction of metabolic and respiratory acidosis.
The ADVOS method works with typical dialysis accesses and flow rates and does not require any gas exchangers for CO2 elimination.